Literature DB >> 27308625

Breaking a paradigm: IL-6/STAT3 signaling suppresses metastatic prostate cancer upon ARF expression.

Zoran Culig1, Jan Pencik2, Olaf Merkel2, Lukas Kenner3.   

Abstract

Interleukin 6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) signaling is considered to have important oncogenic functions in prostate cancer (PCa). However, a recent study highlighted the central role of IL-6/STAT3 signaling in regulation of the ARF-MDM2-p53 senescence axis. This reversal of the postulated oncogenic properties of IL-6/STAT3 signaling in PCa has important therapeutic implications.

Entities:  

Keywords:  ARF; CDK4/CDK6 inhibitors; IL-6; Metastasis; Prostate cancer; STAT3; Senescence

Year:  2016        PMID： 27308625      PMCID： PMC4905394          DOI： 10.1080/23723556.2015.1090048

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  The history and future of targeting cyclin-dependent kinases in cancer therapy.

Authors:  Uzma Asghar; Agnieszka K Witkiewicz; Nicholas C Turner; Erik S Knudsen
Journal:  Nat Rev Drug Discov       Date:  2015-02       Impact factor: 84.694

2.  Interleukin-6 is an autocrine growth factor in human prostate cancer.

Authors:  D Giri; M Ozen; M Ittmann
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

3.  TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.

Authors:  Dewan M S Hossain; Sumanta K Pal; Dayson Moreira; Priyanka Duttagupta; Qifang Zhang; Haejung Won; Jeremy Jones; Massimo D'Apuzzo; Stephen Forman; Marcin Kortylewski
Journal:  Clin Cancer Res       Date:  2015-05-12       Impact factor: 12.531

4.  Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone.

Authors:  M Drobnjak; I Osman; H I Scher; M Fazzari; C Cordon-Cardo
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

5.  The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study.

Authors:  Jayaprakash Karkera; Hannes Steiner; Weimin Li; Viktor Skradski; Patrizia L Moser; Sabine Riethdorf; Manjula Reddy; Thomas Puchalski; Karim Safer; Uma Prabhakar; Klaus Pantel; Ming Qi; Zoran Culig
Journal:  Prostate       Date:  2011-02-14       Impact factor: 4.104

6.  Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells.

Authors:  Soo Ok Lee; Wei Lou; Min Hou; Fernando de Miguel; Lizabeth Gerber; Allen C Gao
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

7.  Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.

Authors:  Lauren Wallner; Jinlu Dai; June Escara-Wilke; Jian Zhang; Zhi Yao; Yi Lu; Mohit Trikha; Jeffrey A Nemeth; Mohamed H Zaki; Evan T Keller
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

8.  Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies.

Authors:  Ken Tawara; Julia T Oxford; Cheryl L Jorcyk
Journal:  Cancer Manag Res       Date:  2011-05-18       Impact factor: 3.989

Review 9.  The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention.

Authors:  John P Alao
Journal:  Mol Cancer       Date:  2007-04-02       Impact factor: 27.401

10.  STAT3 regulated ARF expression suppresses prostate cancer metastasis.

Authors:  Jan Pencik; Michaela Schlederer; Wolfgang Gruber; Christine Unger; Steven M Walker; Athena Chalaris; Isabelle J Marié; Melanie R Hassler; Tahereh Javaheri; Osman Aksoy; Jaine K Blayney; Nicole Prutsch; Anna Skucha; Merima Herac; Oliver H Krämer; Peter Mazal; Florian Grebien; Gerda Egger; Valeria Poli; Wolfgang Mikulits; Robert Eferl; Harald Esterbauer; Richard Kennedy; Falko Fend; Marcus Scharpf; Martin Braun; Sven Perner; David E Levy; Tim Malcolm; Suzanne D Turner; Andrea Haitel; Martin Susani; Ali Moazzami; Stefan Rose-John; Fritz Aberger; Olaf Merkel; Richard Moriggl; Zoran Culig; Helmut Dolznig; Lukas Kenner
Journal:  Nat Commun       Date:  2015-07-22       Impact factor: 14.919
  10 in total
  6 in total

1.  Prostate cancer health disparities: An immuno-biological perspective.

Authors:  Sanjay Kumar; Rajesh Singh; Shalie Malik; Upender Manne; Manoj Mishra
Journal:  Cancer Lett       Date:  2017-11-15       Impact factor: 8.679

Review 2.  Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer.

Authors:  A Fucic; A Aghajanyan; Z Culig; N Le Novere
Journal:  Pathol Oncol Res       Date:  2018-09-16       Impact factor: 3.201

3.  Interleukin-6 and Interferon-α Signaling via JAK1-STAT Differentially Regulate Oncolytic versus Cytoprotective Antiviral States.

Authors:  Oded Danziger; Tal Pupko; Eran Bacharach; Marcelo Ehrlich
Journal:  Front Immunol       Date:  2018-01-30       Impact factor: 7.561

4.  IRE1α Expedites the Progression of Castration-Resistant Prostate Cancers via the Positive Feedback Loop of IRE1α/IL-6/AR.

Authors:  Fan Yang; Chong Yuan; Dan Wu; Jing Zhang; Xingchun Zhou
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244

5.  GCN5 inhibition prevents IL-6-induced prostate cancer metastases through PI3K/PTEN/Akt signaling by inactivating Egr-1.

Authors:  Guangfeng Shao; Yuqiang Liu; Tianjia Ma; Lei Zhang; Mingzhen Yuan; Shengtian Zhao
Journal:  Biosci Rep       Date:  2018-11-30       Impact factor: 3.840

Review 6.  JAK-STAT signaling in cancer: From cytokines to non-coding genome.

Authors:  Jan Pencik; Ha Thi Thanh Pham; Johannes Schmoellerl; Tahereh Javaheri; Michaela Schlederer; Zoran Culig; Olaf Merkel; Richard Moriggl; Florian Grebien; Lukas Kenner
Journal:  Cytokine       Date:  2016-06-24       Impact factor: 3.861
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.